Skip to main content
Premium Trial:

Request an Annual Quote

Verinata Health Moves into Larger Facility with Initial Annual Capacity of 150K Tests

Premium

This article was originally published Dec. 12.

Verinata Health said last week that is has relocated its corporate headquarters and laboratory to a "much larger" facility in Redwood City, Calif.

The move comes as the company prepares to launch in the first quarter of 2012 a next-generation sequencing-based non-invasive prenatal test for multiple chromosomal abnormalities. According to CEO Caren Mason, the new facility demonstrates the firm's "commitment to appropriately prepare for the growth and expansion expected with the launch" of the test.

The new clinical laboratory has an initial capacity of 150,000 tests per year, and the firm's R&D laboratory has been expanded "substantially," according to the company. Space is available for both laboratories to grow further in the future.

Verinata raised about $46.5 million in a Series C financing round this summer. This fall, the company said it has settled on the Illumina HiSeq 2000 as a platform for its test.

Verinata's test is expected to compete with Sequenom's MaterniT21 test for Down syndrome, which Sequenom launched this fall (CSN 10/19/2011), also using the Illumina HiSeq platform. Both firms claim IP rights to the underlying technology (CSN 9/7/2011).

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.